decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 2002 OIG Advisory Opinions / Opinion 02-16 - Scientific Study Allowed to Waive Copayments
Subscribe or sign in to view the full article.
Article Overview
This summary reviews an Office of Inspector General advisory opinion involving a federally sponsored scientific study and the permissibility of waiving copayments for participating Medicare patients. It is relevant to compliance, fraud and abuse, and health care organizations involved in research, reimbursement, and patient cost-sharing policies. The article focuses on the circumstances of the study and the agency’s rationale at a high level.
Why This Topic Matters
Understanding this advisory opinion helps compliance and research administrators assess how OIG views cost-sharing waivers in a federally sponsored study setting. It is useful for organizations that support clinical research, manage Medicare participant billing, or review anti-kickback risk in study-related arrangements.
What You Will Learn
- How an OIG advisory opinion addressed a study-related copayment waiver
- What general factors the agency considered in evaluating the research arrangement
- Why the study context and sponsorship were relevant to the advisory opinion
- How compliance teams can think about research-related cost-sharing issues at a high level
Who Should Read This
- Compliance officers
- Healthcare attorneys
- Research administrators
- Revenue cycle staff
- Medical billing professionals
- HIM/coding professionals with compliance responsibilities
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com